Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

BH-14-030
Cancer - Leukemia, Cancer
Syed Ali, MD

D’Amour Center for Cancer Care

 3350 Main Street

Springfield MA 01199

The purpose of this study is to compare the effects, good and/or bad, of a combination of carfilzomib, lenalidomide and dexamethasone with another combination of bortezomib, lenalidomide and dexamethasone.
Newly diagnosed multiple myeloma
Katie Colbeck
413-794-9875